Skip to main content
SpringerLink
Log in

Afatinib cost effective for advanced squamous NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 euros

  2. progression-free survival

Reference

  • Pignata M, et al. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. ClinicoEconomics and Outcomes Research 2017: 655-668, No. 9, 25 Oct 2017. Available from: URL: https://doi.org/10.2147/CEOR.S136657

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib cost effective for advanced squamous NSCLC. PharmacoEcon Outcomes News 791, 10 (2017). https://doi.org/10.1007/s40274-017-4494-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4494-6

Search

Navigation